Boehringer Ingelheim works to discover and develop innovative, safe and effective ways to treat and prevent some of the world's most challenging diseases.
As an innovative pharmaceutical company, Boehringer Ingelheim has a large and experienced global team managing and conducting clinical trials in many indications. We are committed to the safety of patients who take part in our clinical trials and holding the highest standards in all of our research initiatives. Such trials are conducted to establish the potential of drugs under investigation to progress to becoming new medicines. They are fundamental to developing novel treatments of therapeutic benefit.
Our trials are conducted according to agreed international standards and in compliance with all respective regulations.
In the past decade, Boehringer Ingelheim conducted or sponsored 1,223 studies with 125 substances including approximately 1.2 million patients. Study centres located in 58 countries all over the world.
Landmark trials are large-scale,randomised, controlled clinical trials with thousands of patientsrecruited from a great number of sites around the world. Results have apotential to broadly impact on clinical practice.
Overview: Our Landmark Trials